NASDAQ
16.09.25 | 22:00
3,410 US-Dollar
-4,48 % -0,160
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| C4 THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Di | Barclays bestätigt "Overweight"-Rating für C4 Therapeutics | 1 | Investing.com Deutsch | ||
| Di | C4 Therapeutics stock rating reiterated as Overweight by Barclays | 2 | Investing.com | ||
| Di | Why C4 Therapeutics Stock Crushed the Market on Monday | 2 | The Motley Fool | ||
| Mo | Stephens-Upgrade beflügelt C4 Therapeutics-Aktie mit über 125 % Kurspotenzial | 5 | Investing.com Deutsch | ||
| Mo | C4 Therapeutics stock surges after Stephens upgrade signals upside | 4 | Investing.com | ||
| 04.09. | C4 Therapeutics, Inc.: C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration | 250 | GlobeNewswire (Europe) | WATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science... ► Artikel lesen | |
| 04.09. | C4 Therapeutics stock initiated with Buy rating at Guggenheim on myeloma drug potential | 2 | Investing.com | ||
| 03.09. | C4T to host webcast on cemsidomide multiple myeloma trial data | 2 | Investing.com | ||
| 03.09. | C4 Therapeutics, Inc.: C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting | 6 | GlobeNewswire (USA) | ||
| 07.08. | C4 Therapeutics GAAP EPS of -$0.37 | 14 | Seeking Alpha | ||
| 07.08. | C4 Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.08. | C4 Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 18.06. | C4 Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.05. | C4 Therapeutics halts BRAF degrader work to save cash for cemsidomide | 7 | FierceBiotech | ||
| 07.05. | C4 Therapeutics, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 07.05. | C4 Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.05. | C4 Therapeutics, Inc.: C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights | 430 | GlobeNewswire (Europe) | Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100... ► Artikel lesen | |
| 14.04. | C4 Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 27.02. | C4 Therapeutics, Inc.: C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights | 422 | GlobeNewswire (Europe) | Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma; Trials Expected to Initiate in Early 2026 CFT1946 Phase 1/2 Trial... ► Artikel lesen | |
| 14.01. | C4 Therapeutics, Inc.: C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology | 262 | GlobeNewswire (Europe) | Cemsidomide Data Presented at American Society of Hematology (ASH) Annual Meeting Support Best-in-Class Profile; Program Advancing to Next Phase of Clinical Development in Multiple Myeloma and Non-Hodgkin's... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 1,910 | -1,55 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights | On track to submit Biologics License Application (BLA) for INO-3107 in 2H25, with the goal of file acceptance by year end
Completed design verification (DV) testing... ► Artikel lesen | |
| OCUGEN | 0,991 | -2,44 % | Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | Upfront fees and near-term development milestone payments totaling up to $7.5 millionPotential sales milestones of $180 million or more in first 10 years of commercializationRoyalties equaling 25%... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,690 | -2,76 % | Cardiff Oncology nach Daten-Dip: Jetzt kaufen? | Cardiff Oncology legt seine lang erwarteten Krebs-Daten vor und der Aktienkurs fährt Achterbahn: Bietet sich für Anleger ein neues Trading-Fenster, oder lässt man jetzt besser die Finger von dem Titel?... ► Artikel lesen | |
| CELLDEX THERAPEUTICS | 21,000 | 0,00 % | Celldex Therapeutics, Inc.: Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE) | Study met primary endpoint demonstrating barzolvolimab's ability to potently deplete mast cells in the gastrointestinal tractProfound mast cell depletion did not result in improved clinical outcomes... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,171 | +7,98 % | Strategiewechsel bei Coherus: Voller Fokus auf Immunonkologie | ||
| NEOVACS | 0,380 | 0,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON 18.07.2025 | The following instruments on XETRA do have their first trading 18.07.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 18.07.2025
Aktien
1 KYG7388C1033 Qunabox Group Ltd.
2... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 18,090 | -0,28 % | Cathie Wood's ARK ETF adjusts holdings, ARCT and TEM in focus | ||
| ULTRAGENYX | 24,800 | +0,81 % | Ultragenyx stock maintains Buy rating at H.C. Wainwright on strong GSD1a data | ||
| GYRE THERAPEUTICS | 6,650 | 0,00 % | GYRE THERAPEUTICS, INC. - 8-K, Current Report | ||
| GOSSAMER BIO | 2,740 | +1,56 % | Gossamer Bio stock maintains Buy rating at H.C. Wainwright with $10 price target | ||
| BIOMEA FUSION | 2,025 | +3,32 % | Biomea Fusion, Inc.: Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate ... | ||
| JANUX THERAPEUTICS | 23,410 | -0,64 % | Janux is a new Buy at Truist ahead of catalyst rich H2 | ||
| SAGIMET BIOSCIENCES | 5,400 | 0,00 % | Sagimet Biosciences Inc.: Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit | ||
| 4D MOLECULAR THERAPEUTICS | 6,690 | -1,62 % | 4D Molecular Therapeutics, Inc.: 4DMT Announces New Employment Inducement Grants | EMERYVILLE, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted... ► Artikel lesen | |
| TENAYA THERAPEUTICS | 1,260 | +5,00 % | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | Enrollment Complete in Cohorts 1 and 2 of MyPEAK-1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB Safety Review Enables Enrollment of Expansion Cohorts Cohort 1 of RIDGE-1 Phase... ► Artikel lesen |
C4 THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -4,48 % bei einem Aktienkurs von 3,410 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu C4 THERAPEUTICS INC finden Sie auf Wallstreet Online.